CN102988382B - Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer - Google Patents
Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer Download PDFInfo
- Publication number
- CN102988382B CN102988382B CN201210468725.4A CN201210468725A CN102988382B CN 102988382 B CN102988382 B CN 102988382B CN 201210468725 A CN201210468725 A CN 201210468725A CN 102988382 B CN102988382 B CN 102988382B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- ulcer
- treating
- day
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of Houttuynoid C for preparing a medicine for treating or preventing dental ulcer. The application of Houttuynoid C for preparing the medicine for treating dental ulcer is disclosed for the first time; because the skeleton type belongs to a brand new skeleton type and the dental ulcer curative activity of Houttuynoid C is strong unexpectedly, the possibility that other compounds give any inspiration does not exist; Houttuynoid C has outstanding substantive characteristics; and simultaneously, Houttuynoid C has obvious progress for treating dental ulcer.
Description
Technical field
The present invention relates to the application of Houttuynoid C in preparation treatment or preventing canker sore medicine.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus(1975) investigation 1587 people, prevalence is 20%.As can be seen here, oral ulcer patient is a very huge colony.The cause of disease of recurrent oral ulceration is complicated, still indefinite so far, may infect with viral infection, antibacterial and the factor such as the endocrine regulation of body, immune dysfunction relevant.
The primary treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, and because topical therapeutic toxic and side effects is lower, the people who has therefore obtained people can.Although the buccal tablets that the part occurring is in recent years used carries, easy to use, mouthfeel and compliance are better, and as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields at aspects such as sterilization, antiinflammatory, pain relievings.
The compound H outtuynoid C the present invention relates to is one and within 2012, delivers (Cai, J. Y. et al., 2012. Houttuynoid C, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to DEF(Cai, J. Y. et al., 2012. Houttuynoid C, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.), purposes for the Houttuynoid C the present invention relates in preparation treatment stomatocace medicine belongs to open first, because framework types belongs to brand-new framework types, and its treatment oral ulcer is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, be used for the treatment of oral ulcer simultaneously and obviously there is significant progress.
Summary of the invention
The invention provides the application of Houttuynoid C in preparation treatment or preventing canker sore medicine.
Described compound H outtuynoid C-structure is as shown in formula I:
Formula I
The purposes of the Houttuynoid C the present invention relates in preparation treatment stomatocace medicine belongs to open first, because framework types belongs to brand-new framework types, and its treatment oral ulcer is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, be used for the treatment of oral ulcer simultaneously and obviously there is significant progress.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Cai, J. Y. et al., 2012. Houttuynoid C, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Test example 1 Houttuynoid C anti-oral ulcer experimental study
1, test objective: whether manufacture oral ulcer model with phenol, give the Houttuynoid C of the certain number of times of oral ulcer rat model every day, observing Houttuynoid C has the effect that reduces ulcer.
2, tested medicine and reagent
Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol
Animal: Wistar rat, male, body weight 240 ~ 280
3, test method
Get 50 of rats, male, body weight 240 ~ 280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, after anesthesia by the plastic dropper of 90% phenol cotton balls (internal diameter: 3mm) lower end is flat on the cheek film at the about 1mm of rats with left bicker place, calcination 30min, is shown in the white infringement that this locates about 3mm.Grouping immediately after 24 hours,, divides 5 groups, i.e. model group (4 times/day of adjuvants, containing medicine) by 10 every group; Houttuynoid C high dose group (4 times/day, 0.5mg/ time); Dosage in Houttuynoid C (4 times/day, 0.1mg/ time); Houttuynoid C low dose group (4 times/day, 0.02mg/ time); Positive controls: cydiodine group (4 times/day, 0.5mg/ time).Houttuynoid C and cydiodine buccal tablet be pulverize before use, and administration be take flap coverage as degree.Successive administration 5 days, after the front and each administration of administration, observe ulcer area size (in the diameter of ulcer) and ulcer healing situation (being considered as healing without macroscopic ulcer) next day, and first administration to last administration is recorded as respectively 1,2,3,4,5,6 day.Ulcer area size is checked with t, ulcer healing rate X
2check.
4, result of the test
Ulcer area comparison (table 1): Houttuynoid C high dose group and model group comparison, from administration, within the 3rd day, play off-test, relatively there is significant difference corresponding every day; Cydiodine group and model group comparison, play off-test on the 3rd day from administration, relatively has significant difference corresponding every day; Dosage group and model group comparison in Houttuynoid C, play off-test on the 3rd day from administration, relatively has significant difference corresponding every day; Houttuynoid C low dose group and model group comparison, play off-test on the 5th day from administration, relatively has significant difference corresponding every day; Dosage group and the comparison of cydiodine group in Houttuynoid C, play off-test on the 1st day from administration, relatively has significant difference corresponding every day.
The impact of table 1 on rat ulcer area
Note: with model group comparison, * p<0.05, * p<0.01.
Healing rate (table 2): adjuvant group and Houttuynoid C low dose group play off-test on the 1st day from administration, ulcer is healing not; And Houttuynoid C high dose group was from administration the 4th day, just there is ulcer healing, to off-test, reach 90%; Cydiodine group, from administration the 4th day, has ulcer healing, to off-test, reaches 60%; In Houttuynoid C, dosage group, from administration the 5th day, has ulcer healing, to off-test, reaches 40%.
The impact of table 2 on rat ulcer healing time
Note: with model group comparison, * p<0.05, * p<0.01.
5, conclusion
Houttuynoid C has the effect of obvious promotion oral ulcer healing.
Claims (1)
- The application of 1.Houttuynoid C in preparation treatment or preventing canker sore medicine, described compound H outtuynoid C-structure as formula Ishown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210468725.4A CN102988382B (en) | 2012-11-19 | 2012-11-19 | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210468725.4A CN102988382B (en) | 2012-11-19 | 2012-11-19 | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102988382A CN102988382A (en) | 2013-03-27 |
| CN102988382B true CN102988382B (en) | 2014-04-16 |
Family
ID=47917810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210468725.4A Expired - Fee Related CN102988382B (en) | 2012-11-19 | 2012-11-19 | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102988382B (en) |
-
2012
- 2012-11-19 CN CN201210468725.4A patent/CN102988382B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| Houttuynoids A-E,anti-herpes simplex virus active flavonoids with novel skeletons from houttuynia cordata;Shao-dan Chen et al.;《Organic Letters》;20120313;第14卷(第7期);第1772-1775页 * |
| Shao-danChenetal..HouttuynoidsA-E anti-herpes simplex virus active flavonoids with novel skeletons from houttuynia cordata.《Organic Letters》.2012 |
| 再吐娜克里木等.鱼腥草治疗复发性口腔溃疡64例.《新疆中医药》.2007,第25卷(第04期), |
| 鱼腥草治疗复发性口腔溃疡64例;再吐娜克里木等;《新疆中医药》;20070831;第25卷(第04期);第49页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102988382A (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768308B (en) | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN103417571A (en) | Composition for treating chicken mycoplasma respiratory infection and preparing method thereof | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103127077A (en) | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN103027918A (en) | Application of Houttuynoid E in preparation of drug for treating or preventing oral ulcer | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN103393655A (en) | Application of Sarcaboside B to medicament for treatment and prevention of oral ulcer | |
| CN103356549A (en) | Application of Sarcaboside A in medicine for treating or preventing oral ulcer | |
| CN103462998A (en) | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer | |
| CN103381160A (en) | Applications of Chukrasone B in medicines used for curing or preventing oral ulcer | |
| CN103505464A (en) | Application of Phyllanthoid A to preparation of medicine for treating or preventing oral ulcer | |
| CN103127086A (en) | Application of Eryngiolide A in medicines curing or preventing dental ulcer | |
| CN103211802A (en) | Novel application of phloroglucinol | |
| CN103638005A (en) | Application of Hippolachnin A in medicine for treatment or prevention of dental ulcer | |
| CN106265638A (en) | Linderolide H application in preparation treatment or preventing canker sore medicine | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN106619604A (en) | Medicine for treating or preventing dental ulcer, and application of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20151119 |
|
| EXPY | Termination of patent right or utility model |